Tesamorelin: The FDA-Approved Peptide Men Use to Burn Visceral Belly Fat

Tesamorelin is a synthetic growth hormone releasing hormone analog and the only peptide currently approved by the FDA specifically for reducing visceral fat. While it was first developed for a niche medical condition, men have adopted it as one of the few tools that selectively targets the deep abdominal fat that drives metabolic disease, without the muscle loss that comes with aggressive dieting or GLP-1 use. This guide covers how it works, how to dose it, and what to expect.

Tesamorelin is a synthetic analog of growth hormone releasing hormone (GHRH), the signal your hypothalamus uses to tell the pituitary gland to release growth hormone. It is the only peptide currently approved by the FDA, sold under the brand name Egrifta, for the specific purpose of reducing excess visceral adipose tissue, the deep fat that surrounds the abdominal organs. Although its original approval was for a niche population, the same mechanism that reduces visceral fat in that group works in healthy men carrying stubborn belly fat that will not respond to diet and training alone.

What makes Tesamorelin distinct from most fat loss tools is its selectivity. It does not suppress appetite like a GLP-1, and it does not force weight loss through caloric deficit. Instead, it restores a more youthful, pulsatile pattern of growth hormone release, which preferentially mobilizes visceral fat while preserving and often improving lean muscle mass. For men over 40 who have a shrinking waistline as their primary goal but who do not want to sacrifice the muscle they have built, this combination of effects is exactly what they are looking for.

Growth hormone is released by the pituitary gland in pulses, mostly during deep sleep, and that pulsatile pattern declines steadily after the age of 30. By the time many men reach their 40s and 50s, the natural growth hormone signal is a fraction of what it was in their 20s, and one of the most visible consequences is the accumulation of visceral fat around the midsection. Tesamorelin works upstream of this problem by binding to GHRH receptors on the pituitary and stimulating the gland to produce and release its own growth hormone in a natural, pulsatile rhythm.

This is an important distinction from injecting synthetic growth hormone directly. Because Tesamorelin works through the body's own regulatory system, it preserves the negative feedback loops that prevent growth hormone from climbing to unsafe levels. The resulting rise in growth hormone increases circulating IGF-1, the downstream hormone responsible for many of growth hormone's effects, and it is this elevation that drives lipolysis in visceral fat stores. Visceral fat is metabolically active and rich in growth hormone receptors, which is why it responds more strongly to this signal than subcutaneous fat does.

Visceral fat is not the soft fat you can pinch under the skin. It is the firm, deep fat packed between and around the liver, intestines, and other organs, and it is the type most strongly linked to insulin resistance, cardiovascular disease, and chronic inflammation. A man can be relatively lean in the arms and chest yet still carry a hard, protruding belly driven by visceral fat, and this pattern becomes more common with age as growth hormone declines and cortisol exposure accumulates. Tesamorelin was specifically designed to attack this depot.

In the pivotal clinical trials, men using Tesamorelin reduced visceral adipose tissue by roughly 15 to 18 percent over 26 weeks, with a measurable reduction in waist circumference and an improvement in the ratio of visceral to subcutaneous fat. Importantly, the fat loss was concentrated in the visceral compartment rather than spread evenly across the body, which is what gives the protocol its reputation for flattening the midsection specifically. When the peptide is stopped, visceral fat tends to return over time, which is why most men treat it as part of a longer term metabolic strategy rather than a quick fix.

One of the most clinically significant findings about Tesamorelin is its effect on liver fat. Non-alcoholic fatty liver disease, now increasingly called metabolic dysfunction associated steatotic liver disease, affects a large and growing share of men over 40 and is closely tied to the same visceral fat accumulation that Tesamorelin targets. Because visceral fat and liver fat are metabolically connected, reducing one tends to reduce the other, and Tesamorelin has shown a direct effect on hepatic fat content in dedicated studies.

In research examining men with excess liver fat, Tesamorelin reduced liver fat fraction by approximately 37 percent over 12 months and prevented the progression of fibrosis in a meaningful share of participants. This makes it one of the few peptides with hard imaging data supporting its use for a serious metabolic condition rather than purely cosmetic fat loss. For men who have been told they have a fatty liver during routine bloodwork or imaging, this effect is often the deciding factor in choosing Tesamorelin over a less targeted approach.

Because GLP-1 drugs like semaglutide and tirzepatide dominate the men's fat loss conversation, the obvious question is how Tesamorelin compares. The honest answer is that they do different things. GLP-1 drugs work by suppressing appetite and slowing gastric emptying, which produces large total weight loss but is not selective about where the fat or the lean mass comes from. A meaningful portion of the weight lost on a GLP-1, often 25 to 40 percent, can be lean muscle if protein intake and training are not managed carefully.

Tesamorelin takes the opposite approach. It does not reduce appetite or total body weight dramatically, but it selectively mobilizes visceral fat while preserving or increasing lean mass through its growth hormone and IGF-1 effects. For a man whose main problem is a hard belly and a fatty liver rather than 60 pounds of excess weight, Tesamorelin is often the better targeted choice. Increasingly, men combine a low dose GLP-1 for appetite control with Tesamorelin for body composition, using each tool for what it does best. You can read more about preventing muscle loss on GLP-1 protocols in our related guides.

The standard Tesamorelin dose is 2mg administered as a subcutaneous injection once daily, most commonly in the evening before bed to align with the body's natural overnight growth hormone pulse. The peptide is reconstituted with sterile or bacteriostatic water and injected into the abdominal fat, rotating sites to avoid irritation. Unlike loading and maintenance peptides, Tesamorelin is typically run at a consistent daily dose rather than cycling between phases, because its effect on visceral fat builds gradually over weeks and is maintained only while the peptide is active.

Most men commit to a minimum of 12 weeks before judging results, with the full visceral fat reduction visible closer to the 26 week mark. Because Tesamorelin raises IGF-1, baseline and follow up bloodwork is essential. A sensible protocol includes a baseline IGF-1, fasting glucose, HbA1c, and lipid panel before starting, with a repeat at 8 to 12 weeks to confirm IGF-1 stays within a safe range and that glucose tolerance has not deteriorated. Some men run Tesamorelin in 6 month blocks followed by a break, while others continue long term under physician supervision for ongoing metabolic benefit.

Tesamorelin has been studied more rigorously than most peptides because it went through the full FDA approval process, and its safety profile is well characterized. The most common side effects are injection site reactions such as redness or itching, joint aches and stiffness, mild swelling from fluid retention, and occasional muscle pain. These effects are usually mild, tend to appear early in the protocol, and often diminish as the body adjusts to the higher growth hormone levels. They are largely the predictable consequences of restoring growth hormone signaling rather than signs of harm.

The more important considerations involve IGF-1 and glucose. Because Tesamorelin raises IGF-1, it should not be used by men with an active malignancy, since IGF-1 can theoretically support the growth of existing cancers. It is also contraindicated in men with disrupted pituitary function or a history of pituitary tumors. Growth hormone can mildly reduce insulin sensitivity, so men with diabetes or prediabetes should monitor their fasting glucose and HbA1c closely. For these reasons, Tesamorelin is best used under the supervision of a physician who orders the appropriate baseline and follow up labs.

Continue Reading

Related Articles

Guide

Fatty Liver Disease in Men: The Silent Diagnosis Most Doctors Do Not Explain

9 min read

Read Article →

Guide

TRT and GLP-1 Together: The 2026 Protocol for Men Who Want It All

8 min read

Read Article →

GLP-1

GLP-1 and Muscle Loss: How to Prevent It in 2026

12 min read

Read Article →

Growth Hormone

Sermorelin vs. Ipamorelin: Which GH Peptide Is Right for You? (2026 Guide)

15 min read

Read Article →